Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study

Keyphrases

• Validation Cohort 100%
• Copy number 100%
• Tumor Tissue 40%
• MAP3K7 20%
• Genetic Modification 20%
• RB1 Deletion 20%
• Gene Set 20%
• Expression Quantitative Trait Loci (eQTL) 20%
• Six Genes 20%
• PTEN Deletion 20%
• Primary Prostate Cancer 20%
• Prostate Cancer Antigen 3 (PCA3) 20%
• Biochemical Relapse 20%
• ZBTB4 20%
• Integrated Genomics 20%
• ELAC2 20%
• MYC Amplification 20%
• Cancer Subgroups 20%
• TPD52 20%
• Molecular Changes 20%
• High-risk Disease 20%
• AMACR 20%
• Heterogeneous Phenotype 20%
• Affective Expression 20%
• Patient Subgroups 20%
• NKX3.1 20%
• Gene Copy number 20%
• Predictors of Poor Prognosis 20%
• Clinical Predictors 20%
• Genome-wide Expression 20%
• Heterogeneous Genotype 20%

Biochemistry, Genetics and Molecular Biology

• PCA3 25%
• Expression Quantitative Trait Loci 25%
• MAP3K7 25%
• Gene Signature 25%